GEHC Quote, Financials, Valuation and Earnings

National Research Corp. has a net margin of 9.02% compared to GE Healthcare Technologies, Inc.'s net margin of 11.54%. GE Healthcare Technologies, Inc.'s return on equity of 24.49% beat National Research Corp.'s return on equity of 61.55%.

GE Healthcare Technologies, Inc. has a consensus price target of $88.11, signalling upside risk potential of 6.78%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that GE Healthcare Technologies, Inc. has higher upside potential than National Research Corp., analysts believe GE Healthcare Technologies, Inc. is more attractive than National Research Corp..

GE Healthcare Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

GE Healthcare Technologies, Inc. has a quarterly dividend of $0.04 per share corresponding to a yield of 0.17%. National Research Corp. offers a yield of 2.94% to investors and pays a quarterly dividend of $0.12 per share. GE Healthcare Technologies, Inc. pays 2.88% of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GE Healthcare Technologies, Inc. quarterly revenues are $5.1B, which are larger than National Research Corp. quarterly revenues of $34.6M. GE Healthcare Technologies, Inc.'s net income of $464M is higher than National Research Corp.'s net income of $4M. Notably, GE Healthcare Technologies, Inc.'s price-to-earnings ratio is 17.06x while National Research Corp.'s PE ratio is 23.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GE Healthcare Technologies, Inc. is 1.87x versus 2.67x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of 9.02% compared to GE Healthcare Technologies, Inc.'s net margin of -2156852.78%. GE Healthcare Technologies, Inc.'s return on equity of 24.49% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

GE Healthcare Technologies, Inc. has a consensus price target of $88.11, signalling upside risk potential of 6.78%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 721.92%. Given that Predictive Oncology, Inc. has higher upside potential than GE Healthcare Technologies, Inc., analysts believe Predictive Oncology, Inc. is more attractive than GE Healthcare Technologies, Inc..

GE Healthcare Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

GE Healthcare Technologies, Inc. has a quarterly dividend of $0.04 per share corresponding to a yield of 0.17%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GE Healthcare Technologies, Inc. pays 2.88% of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend. GE Healthcare Technologies, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GE Healthcare Technologies, Inc. quarterly revenues are $5.1B, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. GE Healthcare Technologies, Inc.'s net income of $464M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, GE Healthcare Technologies, Inc.'s price-to-earnings ratio is 17.06x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GE Healthcare Technologies, Inc. is 1.87x versus 16.78x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of 9.02% compared to GE Healthcare Technologies, Inc.'s net margin of 9.46%. GE Healthcare Technologies, Inc.'s return on equity of 24.49% beat Spok Holdings, Inc.'s return on equity of 10.88%.

GE Healthcare Technologies, Inc. has a consensus price target of $88.11, signalling upside risk potential of 6.78%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.17%. Given that Spok Holdings, Inc. has higher upside potential than GE Healthcare Technologies, Inc., analysts believe Spok Holdings, Inc. is more attractive than GE Healthcare Technologies, Inc..

GE Healthcare Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

GE Healthcare Technologies, Inc. has a quarterly dividend of $0.04 per share corresponding to a yield of 0.17%. Spok Holdings, Inc. offers a yield of 9.59% to investors and pays a quarterly dividend of $0.31 per share. GE Healthcare Technologies, Inc. pays 2.88% of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend. GE Healthcare Technologies, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Spok Holdings, Inc.'s is not.

GE Healthcare Technologies, Inc. quarterly revenues are $5.1B, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. GE Healthcare Technologies, Inc.'s net income of $464M is higher than Spok Holdings, Inc.'s net income of $3.2M. Notably, GE Healthcare Technologies, Inc.'s price-to-earnings ratio is 17.06x while Spok Holdings, Inc.'s PE ratio is 16.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GE Healthcare Technologies, Inc. is 1.87x versus 1.94x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tempus AI, Inc. has a net margin of 9.02% compared to GE Healthcare Technologies, Inc.'s net margin of -23.93%. GE Healthcare Technologies, Inc.'s return on equity of 24.49% beat Tempus AI, Inc.'s return on equity of -81.31%.

GE Healthcare Technologies, Inc. has a consensus price target of $88.11, signalling upside risk potential of 6.78%. On the other hand Tempus AI, Inc. has an analysts' consensus of $91.42 which suggests that it could grow by 19.77%. Given that Tempus AI, Inc. has higher upside potential than GE Healthcare Technologies, Inc., analysts believe Tempus AI, Inc. is more attractive than GE Healthcare Technologies, Inc..

GE Healthcare Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tempus AI, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GE Healthcare Technologies, Inc. has a quarterly dividend of $0.04 per share corresponding to a yield of 0.17%. Tempus AI, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GE Healthcare Technologies, Inc. pays 2.88% of its earnings as a dividend. Tempus AI, Inc. pays out 0.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GE Healthcare Technologies, Inc. quarterly revenues are $5.1B, which are larger than Tempus AI, Inc. quarterly revenues of $334.2M. GE Healthcare Technologies, Inc.'s net income of $464M is higher than Tempus AI, Inc.'s net income of -$80M. Notably, GE Healthcare Technologies, Inc.'s price-to-earnings ratio is 17.06x while Tempus AI, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GE Healthcare Technologies, Inc. is 1.87x versus 11.76x for Tempus AI, Inc.. Usually stocks with elevated PS ratios are considered overvalued.